Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies

Ting Wei Lee; Ting I. Lee; Yung Kuo Lin; Yao Chang Chen; Yu Hsun Kao; Yi Jen Chen

doi:10.1007/s00018-020-03648-y

Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies

Ting Wei Lee, Ting I. Lee, Yung Kuo Lin, Yao Chang Chen, Yu Hsun Kao, Yi Jen Chen

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

Abstract

Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF), which is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Advanced glycation end product and its receptor activation, cardiac energy dysmetabolism, structural and electrical remodeling, and autonomic dysfunction are implicated in AF pathophysiology in diabetic hearts. Antidiabetic drugs have been demonstrated to possess therapeutic potential for AF. However, clinical investigations of AF in patients with DM have been scant and inconclusive. This article provides a comprehensive review of research findings on the association between DM and AF and critically analyzes the effect of different pharmacological classes of antidiabetic drugs on AF.

Original language	English
Pages (from-to)	923-934
Number of pages	12
Journal	Cellular and Molecular Life Sciences
Volume	78
Issue number	3
DOIs	https://doi.org/10.1007/s00018-020-03648-y
Publication status	Published - Feb 2021

Keywords

DPP-4
GLP-1
Metformin
SGLT2
Thiazolidinedione

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Pharmacology
Cellular and Molecular Neuroscience
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00018-020-03648-y

Cite this

@article{3453cdb6788f43f28d0162bd3fa14d02,

title = "Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies",

abstract = "Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF), which is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Advanced glycation end product and its receptor activation, cardiac energy dysmetabolism, structural and electrical remodeling, and autonomic dysfunction are implicated in AF pathophysiology in diabetic hearts. Antidiabetic drugs have been demonstrated to possess therapeutic potential for AF. However, clinical investigations of AF in patients with DM have been scant and inconclusive. This article provides a comprehensive review of research findings on the association between DM and AF and critically analyzes the effect of different pharmacological classes of antidiabetic drugs on AF.",

keywords = "DPP-4, GLP-1, Metformin, SGLT2, Thiazolidinedione",

author = "Lee, {Ting Wei} and Lee, {Ting I.} and Lin, {Yung Kuo} and Chen, {Yao Chang} and Kao, {Yu Hsun} and Chen, {Yi Jen}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature Switzerland AG.",

year = "2021",

month = feb,

doi = "10.1007/s00018-020-03648-y",

language = "English",

volume = "78",

pages = "923--934",

journal = "Cellular and Molecular Life Sciences",

issn = "1420-682X",

publisher = "Birkhauser Verlag Basel",

number = "3",

}

TY - JOUR

T1 - Effect of antidiabetic drugs on the risk of atrial fibrillation

T2 - mechanistic insights from clinical evidence and translational studies

AU - Lee, Ting Wei

AU - Lee, Ting I.

AU - Lin, Yung Kuo

AU - Chen, Yao Chang

AU - Kao, Yu Hsun

AU - Chen, Yi Jen

PY - 2021/2

Y1 - 2021/2

N2 - Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF), which is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Advanced glycation end product and its receptor activation, cardiac energy dysmetabolism, structural and electrical remodeling, and autonomic dysfunction are implicated in AF pathophysiology in diabetic hearts. Antidiabetic drugs have been demonstrated to possess therapeutic potential for AF. However, clinical investigations of AF in patients with DM have been scant and inconclusive. This article provides a comprehensive review of research findings on the association between DM and AF and critically analyzes the effect of different pharmacological classes of antidiabetic drugs on AF.

AB - Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF), which is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Advanced glycation end product and its receptor activation, cardiac energy dysmetabolism, structural and electrical remodeling, and autonomic dysfunction are implicated in AF pathophysiology in diabetic hearts. Antidiabetic drugs have been demonstrated to possess therapeutic potential for AF. However, clinical investigations of AF in patients with DM have been scant and inconclusive. This article provides a comprehensive review of research findings on the association between DM and AF and critically analyzes the effect of different pharmacological classes of antidiabetic drugs on AF.

KW - DPP-4

KW - GLP-1

KW - Metformin

KW - SGLT2

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=85091390428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091390428&partnerID=8YFLogxK

U2 - 10.1007/s00018-020-03648-y

DO - 10.1007/s00018-020-03648-y

M3 - Review article

AN - SCOPUS:85091390428

SN - 1420-682X

VL - 78

SP - 923

EP - 934

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

IS - 3

ER -

Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this